LATIF ZIYAR: Open Payments
NPI 1881699171 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$599 in 29 payments from 6 companies in 2025. Trend: 2023 $413 · 2024 $440 · 2025 $599
Food & beverage: $599
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $264 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $170 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
Products named: CAPLYTA, FANAPT, HETLIOZ, REXULTI, TRINTELLIX, COBENFY, Qelbree.
Industry payments across CA — which companies pay providers there.
